作者 | 胡青木编辑 | 苏淮2026年开年,AI制药赛道呈现火热景象,与部分AI医疗应用公司的商业化困境形成鲜明对比。医药巨头赛诺菲,在短短一年内再度与华深智药达成总额高达25.6亿美元的战略合作,依托后者的AI平台,开发针对自身免疫性疾病的双特异性抗体。2025年底港股上市的英硅智能,也在2026年初捷报频传,顺利斩获施维雅8.88亿美元的研发订单,双方聚焦抗肿瘤靶点展开新药开发。英硅智能的...
Source Link作者 | 胡青木编辑 | 苏淮2026年开年,AI制药赛道呈现火热景象,与部分AI医疗应用公司的商业化困境形成鲜明对比。医药巨头赛诺菲,在短短一年内再度与华深智药达成总额高达25.6亿美元的战略合作,依托后者的AI平台,开发针对自身免疫性疾病的双特异性抗体。2025年底港股上市的英硅智能,也在2026年初捷报频传,顺利斩获施维雅8.88亿美元的研发订单,双方聚焦抗肿瘤靶点展开新药开发。英硅智能的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.